Johnson & Johnson (JNJ) tops revenue estimates, reiterates forecast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
J&J profit edges past Street view after deals delay Stelara competition
January 23, 2024 6:23 AM ESTBy Bhanvi Satija and Patrick Wingrove
(Reuters) - Johnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh U.S. competition from biosimilar versions next year.
Separately, the New Jersey-based drugmaker has tentatively agreed to pay about $700 million to settle an investigationbrought by more than 40 states into the marketing of its talc products, J&J told the Wall Street Journal.
J&J confirmed that it had reached an agreement in principle with 43 states to resolve the talc claims... More
Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Beats on Revenue; Reaffirms FY24 Growth Targets
January 23, 2024 6:20 AM EST(Updated - January 23, 2024 6:22 AM EST)
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $2.29, $0.01 better than the analyst estimate of $2.28. Revenue for the quarter came in at $21.4 billion versus the consensus estimate of $21 billion.
The company re-confirms guidance for 2024 with operational sales growth of... More
